Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications

Molecular Cancer Therapeutics

Volumn 15, Issue 4, 2016, Pages 628-639

  Ardini, Elena ^a   Menichincheri, Maria ^a   Banfi, Patrizia ^a   Bosotti, Roberta ^a   De Ponti, Cristina ^a   Pulci, Romana ^b   Ballinari, Dario ^a   Ciomei, Marina ^a   Texido, Gemma ^a   Degrassi, Anna ^a   Avanzi, Nilla ^a   Amboldi, Nadia ^a   Saccardo, Maria Beatrice ^a   Casero, Daniele ^a   Orsini, Paolo ^a   Bandiera, Tiziano ^a   Mologni, Luca ^c   Anderson, David ^d   Wei, Ge ^d   Harris, Jason ^d   Vernier, Jean Michel ^d   Li, Gang ^d   Felder, Eduard ^a   Donati, Daniele ^a   Isacchi, Antonella ^a   Pesenti, Enrico ^b   Magnaghi, Paola ^a   Galvani, Arturo ^a   more..

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b Accelera   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Ignyta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; ENTRECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER REGRESSION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; GENE TRANSLOCATION; GENETICS; METABOLISM; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUMANS; INDAZOLES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; MORTALITY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964355641     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0758     Document Type: Article

References (40)

1. Rikova K, Guo A, Zeng O, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signalling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
2. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 2007;448:561-6.
3. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4.
4. Indo Y. Nerve growth factor and the physiology of pain: lessons from congenital insensitivity to pain with anhidrosis. Clin Genet 2012;82:341-50.
5. Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol 2010;321:44-9.
6. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 2009;15:3244-50.
7. Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, et al. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol 2007;30:193-200.
8. Zhu ZW, Friess H, Wang L, Bogardus T, Korc M, Kleeff J, et al. Nerve Growth Factor exerts differential effects on the growth of human pancreatic cancer cells. Clin Cancer Res 2001;7:105-12.
9. Liu D, Zhang Y, Dand C, Ma Q, Lee W, Chen W. siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway. Oncol Rep 2007;18:673-7.
10. Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009;28:1960-70.
11. Vaishnavi A, Cappelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19:1469-72.
12. Ardini E, Bosotti R, Lombardi Borgia A, De Ponti C, Somaschini A, Cammarota R, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol 2014;8:1495-507.
13. Vaishnavi A, Le AT, Doebele RC. TRKing downan old oncogene in a new era of targeted therapy. Cancer Discov 2015;5:25-34.
14. Kim J, Lee Y, Cho HJ, Lee YE, An J, Cho GH, et al. NTRK1 fusion in glioblastoma multiforme. PLoS One 2014;9:e91940.
15. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014;46:444-50.
16. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanoma. Nat Commun 2014;5:3116.
17. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002;2:367-76.
18. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013;18:865-75.
19. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
20. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 2010;363:1693-703.
21. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010;70:10038-43.
22. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9.
23. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4:120.
24. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALK-positive non-small cell lung cancer. J Thorac Oncol 2013;8:1570-3.
25. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, et al. Synthesis, structureactivity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N4-(2-(isopropylsulfonyl) phenyl) pyrimidine-2, 4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013;56:5675-90.
26. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90.
27. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013;13:772-87.
28. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small cell lung cancer. N Engl J Med 2014;371:1963-71.
29. De Braud FGM, Pilla L, Niger M, Damian S, Bardazza B, Martinetti A, et al. Phase 1 open label, dose escalation study of RXDX-101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 2014;32:5s (suppl; abstr 2502).
30. De Braud FGM, Niger M, Damian S, Bardazza B, Martinetti A, Pelosi G, et al. Alka-372-001: first-in-human, phase I study of entrectinib-an oral pantrk, ROS1, and ALK inhibitor-in patients with advanced solid tumorswith relevant molecular alterations. J Clin Oncol 33, 2015(suppl; abstr 2517).
31. Patel MR, Bauer TM, Liu SV, Drilon A, Wheler J, Shaw A, et al. STARTRK-1: phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumorswith relevant molecular alterations. J Clin Oncol 33, 2015(suppl; abstr 2596).
32. Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, et al. NMSP937, a 4, 5-dihydro-1H-pyrazolo[4, 3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 2011;21:2969-74.
33. Somaschini A, Amboldi N, Nuzzo A, Scacheri E, Ukmar G, Ballinari D, et al. Cell line identity finding by fingerprinting, an optimized resource for short tandem repeat profile authentication. Genet Test Mol Biomarkers 2013;17:254-9.
34. Felder ER, Badari A, Disingrini T, Mantegani S, Orrenius C, Avanzi N, et al. The generation of purinome-targeted libraries as ameans to diversify ATPmimetic chemical classes for lead finding. Mol Divers 2012;16:27-51.
35. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D, et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 2006;103:3153-8.
36. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21:1038-47.
37. Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small cell lung cancer. N Engl J Med 2014;370:2537-9.
38. Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, et al. Phase I trial of lestaurtinib for childrenwith refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol 2011;68:1057-65.
39. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by nextgeneration sequencing. Oncologist 2014;19:235-42.
40. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 2013;19:2040-5.